Skip to content

Study · Animal study (in vivo) · rat · 2021

11 results

NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLP).

Lonati C, Battistin M, Dondossola DE, Bassani GA, Brambilla D, Merighi R, Leonardi P, Carlin A, Meroni M, Zanella A, Catania A, Gatti S

Peptides15 Apr 2021Cited by 18 (Europe PMC)

PMID33865932 (opens in a new tab)DOI10.1016/j.peptides.2021.170552 (opens in a new tab)PepBankPUB-33865932
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs under ex vivo perfusion after ischemia/reperfusion or cardiac death, NDP-MSH reduced the release of inflammatory mediators in perfusates of both groups.

    In plain wordsIn rat lungs perfused outside the body, NDP-MSH reduced inflammatory mediators in the perfusate in both injury groups.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseInflammatory mediators in perfusate (IR and CD)
    Study

    ratn = 20

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    NDP-MSH reduced the release of inflammatory mediators in perfusates of both the IR and the CD groups.
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after ischemia/reperfusion, NDP-MSH treatment was associated with fewer leukocytes (p = 0.034).

    In plain wordsIn rat lungs perfused outside the body after injury, NDP-MSH was linked to fewer white blood cells in the perfusate.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseLeukocytes in perfusate, IR group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    Treatment was likewise associated with a lesser amount of leukocytes (IR: p = 0.034; CD: p = 0.002) and reduced lactate production (IR: p = 0.010; CD: p = 0.008).
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after cardiac death, NDP-MSH treatment was associated with fewer leukocytes (p = 0.002).

    In plain wordsIn rat lungs perfused outside the body after cardiac death, NDP-MSH was linked to fewer white blood cells in the perfusate.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseLeukocytes in perfusate, CD group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    Treatment was likewise associated with a lesser amount of leukocytes (IR: p = 0.034; CD: p = 0.002) and reduced lactate production (IR: p = 0.010; CD: p = 0.008).
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after ischemia/reperfusion, NDP-MSH treatment reduced lactate production (p = 0.010).

    In plain wordsIn rat lungs perfused outside the body after injury, NDP-MSH lowered lactate production.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseLactate production, IR group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Mitochondrial function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    Treatment was likewise associated with a lesser amount of leukocytes (IR: p = 0.034; CD: p = 0.002) and reduced lactate production (IR: p = 0.010; CD: p = 0.008).
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after cardiac death, NDP-MSH treatment reduced lactate production (p = 0.008).

    In plain wordsIn rat lungs perfused outside the body after cardiac death, NDP-MSH lowered lactate production.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseLactate production, CD group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Mitochondrial function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    Treatment was likewise associated with a lesser amount of leukocytes (IR: p = 0.034; CD: p = 0.002) and reduced lactate production (IR: p = 0.010; CD: p = 0.008).
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs exposed to ischemia/reperfusion injury, the NDP-MSH group had increased ATP content compared with controls (p = 0.040).

    In plain wordsIn rat lungs perfused outside the body after injury, NDP-MSH raised ATP content compared with controls.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseATP content, IR group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Mitochondrial function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    In lungs exposed to IR injury, the NDP-MSH group showed increased ATP content (p = 0.040) compared to controls.
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after cardiac death, NDP-MSH produced a significant improvement of vascular parameters (p = 0.002).

    In plain wordsIn rat lungs perfused outside the body after cardiac death, NDP-MSH improved blood vessel measures compared with controls.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableVascular parameters, CD group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    In CD lungs, a significant improvement of vascular (p = 0.002)
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after cardiac death, NDP-MSH produced a significant improvement of airway parameter Ppeak (p < 0.001).

    In plain wordsIn rat lungs perfused outside the body after cardiac death, NDP-MSH improved a measure of peak airway pressure compared with controls.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablePeak airway pressure (Ppeak), CD group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    In CD lungs, a significant improvement of vascular (p = 0.002) and airway (Ppeak: p < 0.001, compliance: p < 0.050, pO2: p < 0.001) parameters was observed.
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after cardiac death, NDP-MSH produced a significant improvement of airway compliance (p < 0.050).

    In plain wordsIn rat lungs perfused outside the body after cardiac death, NDP-MSH improved lung compliance compared with controls.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableCompliance, CD group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    In CD lungs, a significant improvement of vascular (p = 0.002) and airway (Ppeak: p < 0.001, compliance: p < 0.050, pO2: p < 0.001) parameters was observed.
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rat lungs after cardiac death, NDP-MSH produced a significant improvement of pO2 (p < 0.001).

    In plain wordsIn rat lungs perfused outside the body after cardiac death, NDP-MSH improved pO2 compared with controls.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablepO2, CD group
    Study

    ratn = 10

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Comparator
    Untreated controls
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · before lung procurement and during EVLPAs given in this study (rat).

    Source sentences

    Summary
    In CD lungs, a significant improvement of vascular (p = 0.002) and airway (Ppeak: p < 0.001, compliance: p < 0.050, pO2: p < 0.001) parameters was observed.
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 11AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Mechanism

    In rat lungs, expression of MC1R and MC5R was detected in both native and ex vivo-perfused lungs.

    In plain wordsIn rat lungs, the MC1R and MC5R receptors were detected in both native and ex vivo perfused lungs.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableMC1R and MC5R expression in lungs
    Study

    ratn: not reported in source

    ex vivo lung perfusion after ischemia/reperfusion or cardiac death
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    Finally, the expression of MC1R and MC5R was detected in both native and ex vivo-perfused lungs.
    2 context sentences
    Summary · context
    Rats were assigned to one of the following protocols (N = 10 each): 1) ischemia/reperfusion (IR) or 2) cardiac death (CD) followed by ex vivo perfusion.
    Summary · context
    NDP-MSH treatment was performed in five rats of each protocol before lung procurement and during EVLP.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.